From Specialty Pharmacy News - The FDA approved the first biosimilar product, Sandoz Inc.’s Zarxio (filgrastim-sndz), earlier this month, and the industry expects more such approvals. So how should payers be preparing for this new class of drugs? In cases such as Zarxio’s in which the FDA grants indication extrapolation for a biosimilar (see story, p. 1), “Payers need to be really thinking through what it means for their commercial opportunities,” says Gillian Woollett, M.A., D.Phil., senior vice president and head of the FDA Practice at Avalere Health LLC. Read more
From Specialty Pharmacy News - BlueCross BlueShield of Tennessee Inc. (BCBST) is working with Tennessee Oncology, PLLC on a six-month pilot program that’s focused on improving the coordination of care and outcomes for people with cancer. The plan says that “the pilot should lead to better symptom management, fewer emergency room visits and fewer unnecessary treatments.” BCBST members, it says, “will also have 24/7 access to a team of care coordinators trained to help manage their… Read more
From Drug Benefit News - When reporting fourth quarter and full year financial results for 2014, the big three publicly traded PBMs stressed the importance of getting off on the right foot with new clients through seamless implementations. At the same time, they boasted about their various competencies in managing specialty pharmacy costs, calling them a key sales differentiator for 2016 and beyond. Read more
Check out all of the benefits, sample issues & more!